Citigroup Inc Selecta Biosciences Inc Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.62 - $0.85 $1,535 - $2,105	2,477 Added 12.8%	21,824 $18,000
Q4 2023 Feb 09, 2024	BUY	$0.67 - $1.35 $11,739 - $23,654	17,522 Added 960.11%	19,347 $13,000
Q3 2023 Nov 09, 2023	SELL	$1.02 - $1.23 $36,069 - $43,495	-35,362 Reduced 95.09%	1,825 $1,000
Q2 2023 Aug 10, 2023	SELL	$1.04 - $1.4 $159,831 - $215,157	-153,684 Reduced 80.52%	37,187 $41,000
Q1 2023 May 11, 2023	SELL	$1.15 - $1.89 $129,707 - $213,171	-112,789 Reduced 37.14%	190,871 $265,000
Q4 2022 Feb 09, 2023	BUY	$0.96 - $1.6 $278,204 - $463,673	289,796 Added 2090.28%	303,660 $343,000
Q3 2022 Nov 10, 2022	BUY	$1.33 - $2.6 $10,274 - $20,085	7,725 Added 125.83%	13,864 $23,000
Q2 2022 Aug 10, 2022	SELL	$0.67 - $1.4 $1,425 - $2,979	-2,128 Reduced 25.74%	6,139 $8,000
Q1 2022 May 12, 2022	SELL	$1.23 - $3.31 $23,667 - $63,691	-19,242 Reduced 69.95%	8,267 $10,000
Q4 2021 Feb 10, 2022	SELL	$2.89 - $4.43 $245,650 - $376,550	-85,000 Reduced 75.55%	27,509 $90,000
Q3 2021 Nov 10, 2021	BUY	$3.36 - $4.62 $378,030 - $519,791	112,509 New	112,509 $468,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.